Dana-Farber's Guru Sonpavde, MD discusses two studies with promising results. One study looks at pre-operative therapy, the other study compares an antibody-drug conjugate to chemotherapy in urothelial carcinoma.
two recent bladder cancer studies offering exciting advances. Both studies were presented at the 2021 Janet Ordinary Cancers Symposium, Dana Farber's doctor Gurus and Poverty says one Phase three study looked at an immunotherapy drug before surgery for patients with high risk, muscle invasive urethral carcinoma. Doctors in Poverty says. In this setting, there hasn't been any achievement or preoperative therapy proven to improve survival. But now there's promising research. Now for the first time here with the Checkmate 274 trial, we have a positive actual trial that looked at naval a man in patients with high risk muscle invasive your material. Kostroma. So in this group of patients, a German naval map improved disease free survival in all comers, everybody regardless of period one, and also in patients who were period l one high. So this is a very exciting advance for, uh, for us in this field. Dr. San Poverty was not involved in that research. Another Phase three bladder cancer study, in which doctor some poverty is one of the investigators, looks at the antibody drug conjugate in Fort a mob Vidovdan and compares it to chemotherapy in patients with previously treated locally advanced or metastatic urethral carcinoma. And the good news is that this tribe was positive. At interim analysis, the endpoint of survival was met, which does confirm that there was an improvement in survival with a hazard ratio 0.70 foreign for them my vote in compared to historical taxis or when food and chemotherapy. So I think this establishes in for the member road and as a new standard of care as third line therapy in patients with progressive metastatic your material carcinoma, post platinum based chemotherapy and Perry one l one inhibition. Doctors in Poverty says both of these trials offer hope for bladder cancer patients, and he's looking forward to follow up studies.
